Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Dahut

Showing results (11-20 of 146) with videos related to

Pageof 15
Sort By:
JAMA|July 15, 2005
Androgen deprivation therapy for prostate cancerNima Sharifi, James L Gulley, William L Dahut
Endocrine-Related Cancer|September 24, 2010
An update on androgen deprivation therapy for prostate cancerNima Sharifi, James L Gulley, William L Dahut
American Journal of Therapeutics|January 6, 2004
The emerging role of bisphosphonates in prostate cancerEdwin M Posadas, William L Dahut, James Gulley
Current Treatment Options in Oncology|April 24, 2017
Management Options for Biochemically Recurrent Prostate CancerFarhad Fakhrejahani, Ravi A Madan, William L Dahut
BJU International|October 10, 2007
Secondary hormonal therapy for prostate cancer: what lies on the horizon?Nima Sharifi, William L Dahut, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
The genetics of castration-resistant prostate cancer: what can the germline tell us?Nima Sharifi, William L Dahut, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2020
The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global PandemicFatima Karzai, Ravi A Madan, William L Dahut
Acta Oncologica (Stockholm, Sweden)|June 15, 2007
The use of bisphosphonates in cancer patientsShenhong Wu, William L Dahut, James L Gulley
Clinical Advances in Hematology & Oncology : H&O|October 18, 2005
Treatment options for androgen-independent prostate cancerJames Gulley, William D Figg, William L Dahut
Future Oncology (London, England)|April 13, 2016
Metabolic syndrome in prostate cancer: impact on risk and outcomesFatima H Karzai, Ravi A Madan, William L Dahut
Pageof 15

Showing results (11-20 of 146) with videos related to

Sort By:
Pageof 15
JAMA|July 15, 2005
Androgen deprivation therapy for prostate cancerNima Sharifi, James L Gulley, William L Dahut
Endocrine-Related Cancer|September 24, 2010
An update on androgen deprivation therapy for prostate cancerNima Sharifi, James L Gulley, William L Dahut
American Journal of Therapeutics|January 6, 2004
The emerging role of bisphosphonates in prostate cancerEdwin M Posadas, William L Dahut, James Gulley
Current Treatment Options in Oncology|April 24, 2017
Management Options for Biochemically Recurrent Prostate CancerFarhad Fakhrejahani, Ravi A Madan, William L Dahut
BJU International|October 10, 2007
Secondary hormonal therapy for prostate cancer: what lies on the horizon?Nima Sharifi, William L Dahut, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
The genetics of castration-resistant prostate cancer: what can the germline tell us?Nima Sharifi, William L Dahut, William D Figg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2020
The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global PandemicFatima Karzai, Ravi A Madan, William L Dahut
Acta Oncologica (Stockholm, Sweden)|June 15, 2007
The use of bisphosphonates in cancer patientsShenhong Wu, William L Dahut, James L Gulley
Clinical Advances in Hematology & Oncology : H&O|October 18, 2005
Treatment options for androgen-independent prostate cancerJames Gulley, William D Figg, William L Dahut
Future Oncology (London, England)|April 13, 2016
Metabolic syndrome in prostate cancer: impact on risk and outcomesFatima H Karzai, Ravi A Madan, William L Dahut
Pageof 15